Padmanee Sharma
#114,466
Most Influential Person Now
Researcher
Padmanee Sharma's AcademicInfluence.com Rankings
Padmanee Sharmaphilosophy Degrees
Philosophy
#4916
World Rank
#7595
Historical Rank
Logic
#2279
World Rank
#3240
Historical Rank
Padmanee Sharmabiology Degrees
Biology
#6551
World Rank
#9290
Historical Rank
Immunology
#340
World Rank
#353
Historical Rank
Download Badge
Philosophy Biology
Why Is Padmanee Sharma Influential?
(Suggest an Edit or Addition)Padmanee Sharma's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (4550)
- The future of immune checkpoint therapy (2015) (3376)
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy (2017) (2836)
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma (2018) (2700)
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients (2018) (2594)
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential (2015) (1722)
- The Human Cell Atlas (2017) (1285)
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. (2017) (1243)
- Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. (2014) (1182)
- B cells and tertiary lymphoid structures promote immunotherapy response (2020) (1046)
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. (2016) (975)
- Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. (2015) (890)
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy (2016) (860)
- PD-L1 Expression in Triple-Negative Breast Cancer (2014) (833)
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade (2017) (819)
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. (2016) (685)
- Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. (2015) (601)
- Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011) (578)
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance (2017) (555)
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma (2018) (500)
- CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients (2008) (479)
- CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma (2007) (464)
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial (2010) (409)
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer (2017) (409)
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (400)
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018) (381)
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial (2016) (376)
- Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer (2017) (358)
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. (2017) (334)
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. (2017) (287)
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. (2018) (280)
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) (271)
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? (2014) (260)
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). (2014) (253)
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells (2016) (239)
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy (2014) (235)
- Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers (2018) (231)
- B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome (2007) (228)
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) (215)
- Dissecting the mechanisms of immune checkpoint therapy (2020) (204)
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy (2019) (203)
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. (2017) (201)
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. (2017) (200)
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. (2018) (193)
- The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. (2011) (193)
- Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues (2009) (191)
- The Next Decade of Immune Checkpoint Therapy. (2021) (190)
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial (2016) (186)
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer (2019) (184)
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (2021) (181)
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma (2019) (177)
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer (2018) (177)
- The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (2018) (177)
- Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2014) (171)
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy (2013) (168)
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. (2020) (160)
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities (2016) (160)
- Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. (2017) (160)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma (2015) (147)
- B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. (2008) (142)
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. (2019) (139)
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy (2018) (138)
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes (2018) (137)
- A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling (2016) (135)
- TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. (2017) (134)
- Harnessing the power of the immune system to target cancer. (2013) (130)
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma (2020) (127)
- Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade (2020) (127)
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience (2018) (125)
- Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer (2014) (120)
- Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (110)
- Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma (2017) (105)
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities (2019) (102)
- Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity (2017) (102)
- Monitoring immune responses in the tumor microenvironment. (2016) (94)
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade (2018) (94)
- CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). (2016) (88)
- Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody (2016) (87)
- Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer (2020) (87)
- Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma (2006) (86)
- The emerging role of immune checkpoint based approaches in AML and MDS (2018) (83)
- Radiomics to predict immunotherapy-induced pneumonitis: proof of concept (2018) (83)
- PD-L 1 Expression in Triple-Negative Breast Cancer (2014) (83)
- A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. (2020) (82)
- Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. (2021) (80)
- Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. (2019) (80)
- Cancer Immunotherapy: Sipuleucel‐T and Beyond (2011) (78)
- Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy (2016) (78)
- Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). (2019) (78)
- Strategies for combining immunotherapy with radiation for anticancer therapy. (2015) (77)
- Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2015) (75)
- Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. (2003) (74)
- Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. (2019) (74)
- NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells (2009) (73)
- Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. (2019) (72)
- Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (2017) (71)
- Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study. (2016) (70)
- Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. (2007) (70)
- Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses (2019) (65)
- Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) (2016) (61)
- Negative Co‐stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States (2019) (60)
- Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy (2018) (59)
- Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313) (2017) (58)
- ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC (2020) (58)
- Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial (2016) (56)
- Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn’s disease: a case report (2016) (55)
- Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275 (2020) (54)
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies (2017) (54)
- Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma (2016) (53)
- Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. (2020) (53)
- Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF (2008) (53)
- ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. (2016) (51)
- 848PDImpact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study (2017) (50)
- Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. (2020) (49)
- CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. (2015) (48)
- Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience (2014) (48)
- Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy (2014) (46)
- Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. (2016) (44)
- Erythema nodosum‐like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients (2017) (44)
- Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade (2017) (44)
- Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma (2019) (42)
- Advances in the development of cancer immunotherapies. (2013) (42)
- Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response (2019) (41)
- Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. (2022) (41)
- Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. (2019) (39)
- CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy (2013) (39)
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (38)
- Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. (2019) (38)
- Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. (2010) (38)
- Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. (2019) (38)
- CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). (2016) (37)
- Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. (2022) (37)
- Immunotherapeutic strategies for high-risk bladder cancer. (2007) (36)
- Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. (2008) (36)
- Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML) (2016) (35)
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study (2019) (35)
- High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer (2019) (33)
- Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (33)
- Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. (2017) (32)
- Immune Checkpoint Therapy and the Search for Predictive Biomarkers (2016) (32)
- Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. (2017) (31)
- Inherited Mutations in Cancer Susceptibility Genes Are Common Among Survivors of Breast Cancer Who Develop Therapy-Related Leukemia (2016) (31)
- Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy (2011) (30)
- Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies (2017) (30)
- Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. (2017) (29)
- Neoadjuvant relatlimab and nivolumab in resectable melanoma (2022) (29)
- Mechanisms of T-cell inhibition: implications for cancer immunotherapy (2010) (29)
- Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. (2020) (28)
- Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck (2021) (28)
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. (2017) (28)
- Characterization and Comparison of GITR Expression in Solid Tumors (2019) (28)
- Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (2018) (27)
- A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation (2018) (27)
- Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study (2016) (27)
- Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors (2020) (26)
- Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer (2021) (25)
- Cancer Immunotherapy Highlights from the 2014 ASCO Meeting (2014) (25)
- NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). (2016) (25)
- Inheritance of blast resistance and its allelic relationship with five major R genes in a rice landrace "Vanasurya" (2014) (25)
- Myeloid cell-targeted therapies for solid tumours (2022) (25)
- MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial (2017) (25)
- Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. (2014) (24)
- Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide. (2012) (24)
- Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner (2019) (24)
- 1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (23)
- Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. (2016) (23)
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2022) (22)
- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. (2018) (22)
- Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma. (2018) (20)
- Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy (2019) (19)
- 1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (18)
- Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses (2019) (18)
- Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer (2015) (18)
- Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study (2018) (16)
- Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study (2016) (16)
- Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy (2021) (16)
- Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma. (2018) (15)
- Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma. (2017) (15)
- Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment (2021) (15)
- A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx). (2018) (15)
- Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. (2017) (15)
- Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML (2017) (15)
- A potential biomarker for anti-PD-1 immunotherapy (2018) (14)
- A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). (2019) (14)
- Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia (2017) (14)
- Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). (2011) (14)
- Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts). (2016) (14)
- First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors (2021) (13)
- Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma (2020) (13)
- Review of metastatic bladder cancer. (2006) (13)
- Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing (2020) (13)
- Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC) (2019) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275. (2019) (12)
- Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer (2021) (12)
- Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275 (2018) (12)
- Phenotyping of improved rice lines and landraces for blast and sheath blight resistance (2014) (11)
- CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC) (2015) (11)
- Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (11)
- Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). (2019) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (2022) (11)
- NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer. (2014) (10)
- Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032. (2018) (10)
- A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy (2022) (10)
- Author response: The Human Cell Atlas (2017) (10)
- Ipilimumab for recurrent glioblastoma: A single-institution case series. (2014) (10)
- Abstract S3-7: Treatment with Histone Deacetylase Inhibitors Creates ‘BRCAness’ and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin (2012) (9)
- Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing (2021) (9)
- Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (9)
- Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. (2018) (9)
- Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI). (2018) (8)
- Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity (2017) (8)
- Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma (2013) (8)
- Focus on TILs: Prognosticsignificance of tumor infiltrating lymphocytes in human bladdercancer (2007) (7)
- Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. (2016) (7)
- Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML) (2016) (7)
- Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence. (2014) (7)
- Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma (2021) (7)
- 674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032 (2017) (7)
- Erratum: Effective combinatorial immunotherapy for castration-resistant prostate cancer (2017) (6)
- Epigenetic changes in T cells in response to immune checkpoint blockade. (2016) (6)
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response (2020) (6)
- Prostate cancer: Combination of vaccine plus ipilimumab—safety and toxicity (2012) (6)
- Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). (2018) (6)
- A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). (2019) (6)
- A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy. (2018) (6)
- Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience. (2018) (5)
- HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2. (2013) (5)
- Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. (2018) (5)
- Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (5)
- An Increased γδ T Cell Population in the Intestine of Thymus-Leukemia Antigen Transgenic Mice☆ (1997) (5)
- Abstract 2672: Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome (2017) (5)
- Genetic biomarker for cancer immunotherapy (2017) (5)
- Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. (2020) (5)
- Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) and sarcomatoid dedifferentiation (sRCC) after treatment with immune checkpoint inhibitors (ICI): A single-institution retrospective study. (2018) (5)
- Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy. (2018) (5)
- Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) (2015) (5)
- A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. (2022) (5)
- Abstract 4026: Epigenetic changes in T cells in response to immune checkpoint blockade (2016) (5)
- From the Guest Editor: Immune Checkpoint Therapy as a Weapon Against Cancer. (2016) (4)
- 749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032 (2020) (4)
- 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) (2015) (4)
- Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM) (2015) (4)
- Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML): Abstract: CI‐026 (2017) (4)
- Erratum: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma [Journal for Immunotherapy of Cancer., 5 (2017)(68)] DOI: 10.1186/s40425-017-0271-0 (2017) (4)
- Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events (2021) (4)
- Abstract PD09-02: BRCA1 insufficiency is predictive of superior survival in patients with triple negative breast cancer treated with platinum based chemotherapy (2012) (3)
- IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
- A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. (2022) (3)
- Correlation of mammographic breast density with Ki-67 expression in benign breast epithelial cells obtained by random periareolar fine needle aspiration of high risk women. (2006) (3)
- Abstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma (2017) (3)
- Association of BRCA1 promoter methylation in triple-negative breast cancer (TNBC) with resistance to standard anthracyline-based adjuvant chemotherapy. (2011) (3)
- Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). (2017) (3)
- Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. (2017) (3)
- Immune co-signaling to treat cancer (2013) (3)
- Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). (2017) (3)
- Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. (2016) (3)
- Association of phosphatidylinositol 3-kinase (PI3K) pathway activation with increased immune checkpoint expression in colorectal cancer (CRC) patients. (2018) (3)
- Targeting the tumor niche to treat cancer (2015) (3)
- Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275. (2017) (3)
- Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML. (2018) (3)
- Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence. (2013) (3)
- Molecular and immune heterogeneity in synchronous melanoma metastases (2015) (3)
- An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. (2021) (2)
- OA20.06 Prospective ImmunogenomiC PrOfiling of Non-Small Cell Lung Cancer - The ICON Project (2017) (2)
- Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study (2016) (2)
- 1053PDFINITE ANDROGEN DEPRIVATION THERAPY (ADT) PLUS IPILIMUMAB (IPI) IN MEN WITH HORMONE-NAïVE METASTATIC PROSTATE CANCER (HN-MPCA). (2014) (2)
- Abstract CT131: NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response (2016) (2)
- Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy (2020) (2)
- Association of the T-cell receptor landscape with survival in non-small cell lung cancer. (2018) (2)
- Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome (2019) (2)
- Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence. (2013) (2)
- Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. (2017) (2)
- Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT (2018) (2)
- CD8+ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients. (2006) (2)
- Th1/17 Cells Are Expanded in Bronchial Alveolar Lavage (BAL) Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis (2017) (2)
- Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host (2010) (2)
- Prognostic implications of TAMs in colorectal cancer hepatic metastases. (2017) (2)
- Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). (2014) (2)
- Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer (2015) (2)
- Abstract P6-11-08: Safety and efficacy results from phase I study of BYL 719 plus nab-paclitaxel in HER 2 negative metastatic breast cancer (2017) (2)
- Combination therapy of adoptive T cell therapy and immune checkpoint blockades engages distinct mechanisms in CD4+ and CD8+ T cells (2018) (2)
- Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial. (2023) (1)
- Investigating genes and micro-RNAs that may predict clinical benefits of anti-CTLA-4 therapy. (2013) (1)
- MA11.09 Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer (2019) (1)
- Abstract A031: Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy (2016) (1)
- OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues (2017) (1)
- Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021 (2022) (1)
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. (2016) (1)
- P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC): Topic: Translational Research and Biomarkers (2017) (1)
- Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT) (2016) (1)
- The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (2021) (1)
- Abstract 5368: A phase II study of ipilumimab plus androgen deprivation therapy in castration-sensitive prostate carcinoma (2012) (1)
- Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates. (2016) (1)
- Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma (2023) (1)
- Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma (2020) (1)
- Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies (2018) (1)
- Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma (2017) (1)
- Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021 (2022) (1)
- Immune checkpoint therapy: Forging ahead (2022) (1)
- Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. (2018) (1)
- Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer (2022) (1)
- Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade (2017) (1)
- A study of genes and microRNAs that may predict clinical responses to anti-CTLA-4 therapy. (2013) (1)
- Abstract A084: High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better survival in non-small cell lung cancer (2016) (1)
- 623 Trial in progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies (2022) (1)
- Focus on TILs (2007) (1)
- Abstract 4388: Combination therapy with anti-CTLA-4 plus leuprolide acetate in the pre-surgical setting of patients with regional, high-risk prostate cancer (2012) (1)
- Molecular characterization of renal medullary carcinoma (RMC). (2014) (1)
- Protein and DNA-Based Vaccines With the NY-ESO-1 Antigen in Cancer Patients (2005) (1)
- Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial (2023) (1)
- Combinatorial biomarkers to predict responses to immune checkpoint therapy in metastatic urothelial cancer. (2021) (1)
- Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma (2017) (1)
- Immune analysis of fibrolamellar hepatocellular carcinoma. (2017) (1)
- Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy (2014) (1)
- Part 2: Targeting Cancer Pathways: The Tumor Microenvironment (2015) (1)
- Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) (2014) (1)
- Abstract OT3-01-12: Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer (2016) (1)
- S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4 (2014) (1)
- Abstract P5-13-03: Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer (2016) (1)
- Abstract OT3-02-06: Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial (2017) (1)
- Last but not Least: Antibody-Drug Conjugates in Hormone Receptor-Positive Metastatic Breast Cancer. (2020) (1)
- Abstract 3570: Adoptive transfer of tumor antigen-specific CTLs requires anti-CTLA-4 and anti-PD-1 to drive tumor eradication (2018) (1)
- Incidence of immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis (2016) (1)
- Abstract IA14: Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4. (2013) (0)
- ICOS signaling in CD8+ CTL contributes to the antitumor efficacy (P2122) (2013) (0)
- 891POutcomes of patients with metastatic renal cell carcinoma (mRCC) who were treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitor (ICI) therapy (2017) (0)
- A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA (2022) (0)
- The Phoenix Rises: The Rebirth of Cancer Immunotherapy. (2017) (0)
- Immunological impact of anti-CTLA4 therapy in a neoadjuvant setting (2008) (0)
- Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. (2022) (0)
- Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. (2011) (0)
- Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities (2015) (0)
- Abstract 1265: Sustained PI3-kinase signaling is mediated by ICOS, not CD28, for anti-tumor T-cell responses elicited by anti-CTLA-4. (2013) (0)
- Phase I Trial of MK-3475 and Concurrent Radiation for the Elimination of Extensive-Stage Small Cell Lung Cancer (2018) (0)
- Abstract PL01-02: Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond (2018) (0)
- Abstract P6-12-11: Feasibility and biomarker modulation due to high levels of moderate to vigorous physical activity as part of a weight loss intervention in older, sedentary, obese breast cancer survivors (2018) (0)
- Abstract 5788: Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets (2023) (0)
- List of Contributors (2019) (0)
- Ablative therapy to induce local and systemic immune changes in patients with metastatic renal cell carcinoma. (2017) (0)
- Abstract IA21: From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy (2020) (0)
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (0)
- Abstract 3776: Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy (2019) (0)
- Lloyd J. Old (1933–2011) (2012) (0)
- Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor‐Induced Pneumonitis: Abstract: CI‐027 (2017) (0)
- Abstract 5590: A phase I/II study of decitabine with pegylated interferon α-2b in advanced melanoma: clinical results and impact on DNA methylation and immune modulation (2012) (0)
- Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. (2023) (0)
- Abstract IA03: From the clinic to the lab: Investigating immune responses to immune checkpoint therapies (2016) (0)
- Abstract 569: MicroRNA-mediated resistance to anti-PD1 therapy in lung cancer (2016) (0)
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma (2018) (0)
- Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor) (2023) (0)
- Abstract IA15: Functional diversity of the pancreas tumor stroma (2016) (0)
- Vesico ureteral reflux: presentation & diagnosis (1988) (0)
- 678P Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI) (2021) (0)
- Abstract 1402: Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer (2016) (0)
- Expression of IFNgR on tumor cells impact response to anti-CTLA-4 (TUM2P.1034) (2015) (0)
- Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy. (2012) (0)
- Abstract P3-13-04: Change in oncotype DX variables and Ki67 response and outcome in women with ER positive early breast cancer treated with neo-adjuvant anastrozole and fulvestrant (2018) (0)
- Comprehensive T cell repertoire characterization of non-small cell lung cancer (2020) (0)
- Immune checkpoint therapy—current perspectives and future directions (2023) (0)
- Abstract 3277: In vivo CRISPR screening identifies PTDSS1 as a potential combinatorial target to improve immune checkpoint therapy response (2023) (0)
- ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS (2018) (0)
- Abstract SY25-03: From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy (2017) (0)
- Predictive Biomarkers and Response to Immunotherapies in Urothelial Cancers (2016) (0)
- 352 Target modulation within the tumor microenvironment (TME) by daratumumab (anti-CD38) but not edicotinib (CSF-1R inhibitor) in men with high-risk localized prostate cancer (2021) (0)
- Anti-CTLA-4 therapy in bladder cancer patients alters immune responses by increasing IFNγ production and decreasing the CD4+FOXP3 + regulatory T cells in the tumor microenvironment (2008) (0)
- Abstract IA24: Immune checkpoint therapy: Immune monitoring on presurgical and tissue-based clinical trials (2016) (0)
- Abstract PD09-07: Breast Cancer Patients with WHO Class II Obesity or Greater (BMI ≥35) Have Poorer Overall Survival after Receiving Chemotherapy Compared to Similar Patients with Lower Body Mass Index (2010) (0)
- Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM) (2018) (0)
- Abstract P1-08-03: Withdrawn (2018) (0)
- Abstract 4890: Mutational signatures as biomarkers of response to nivolumab in metastatic bladder cancer (2019) (0)
- Myeloid-specific KDM6B inhibition sensitizes Glioblastoma to PD1 blockade (2022) (0)
- Analyses of PD-L1 and In fl ammatory Gene Expression Association with Ef fi cacy of Nivolumab (cid:1) Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer (2021) (0)
- Improved Acute Graft‐versus Host Disease (aGVHD) and Progression Free Survival with Post‐Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA‐4 or PD‐1 Blockade: Abstract: CI‐028 (2017) (0)
- Abstract 5927: Leveraging single cell RNA profiling to uncover intra-tumor heterogeneity across cytogenetic subgroups in acute myeloid leukemia (2023) (0)
- A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent (2015) (0)
- Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy (2020) (0)
- Title: A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early- stage breast cancer with comprehensive immune profiling. Authors and affiliations: (2016) (0)
- Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. (2019) (0)
- Cancer Immunity 3:19 (2003)-ARTICLE (2003) (0)
- Phase I Trial of MK-3475 and Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer (2018) (0)
- Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma (2020) (0)
- B cells and tertiary lymphoid structures promote immunotherapy response (2020) (0)
- P1-12-24: Adherence and Persistence with Lapatinib in Women with Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab. (2011) (0)
- Abstract P5-16-02: Pathological complete response is associated with excellent outcomes inBRCAmutation associated triple negative breast cancer (2017) (0)
- Radiotherapy Use and Locoregional Recurrence Rates on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer (2022) (0)
- Dissecting the mechanisms of immune checkpoint therapy (2020) (0)
- 505 High-dimensional analyses of intratumoral myeloid cells highlights presence of distinct myeloid cell phenotypes in immune checkpoint-sensitive and resistant tumors (2022) (0)
- Correlation of statin use with breast random periareolar fine needle aspiration (RPFNA) cytomorphology in high risk postmenopausal women. (2006) (0)
- Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer: Mulligan JM, Hill LA, Deharo S, et al (Queen's Univ Belfast, UK; et al) J Natl Cancer Inst 106:1-10, 2014§ (2014) (0)
- 587 AMADEUS trial: tumor agnostic pre- and on-treatment biomarkers of response to nivolumab plus ipilimumab correlate with on-treatment tumoral T cell infiltration (2022) (0)
- Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer. (2016) (0)
- Abstract P2-14-14: Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2 negative stage II-III breast cancer (2022) (0)
- Evaluation of Ki-67 measured in benign breast tissue acquired from premenopausal women treated with a flaxseed derivative. (2009) (0)
- Abstract P5-14-06: Lapatinib reverses endocrine resistance in select patients with HER2 negative, hormone positive metastatic breast cancer (2016) (0)
- Immunologic impact of anti-CTLA-4 therapy. (2009) (0)
- Vitamin D levels during and after high-dose vitamin D supplementation in women with early-stage breast cancer. (2009) (0)
- Abstract P4-10-06: Influence of older age on triple negative breast cancer (TNBC) clinical-pathological characteristics and outcomes (2018) (0)
- Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. (2013) (0)
- Overall survival effect of lower chemotherapy dosing in extremely obese (BMI ≥ 35) patients with breast cancer based on adjusted BSA. (2011) (0)
- Abstract #5665: Assessing immunologic impact of anti-CTLA-4 therapy on a pre-surgical clinical trial (2009) (0)
- Abstract 2392: Genomic and immune heterogeneity in synchronous melanoma metastases is associated with differential tumor growth and response to therapy (2016) (0)
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma (2019) (0)
- IPILIMUMAB PLUS LENALIDOMIDE FOR TREATMENT OF RELAPSED DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) IN PATIENTS (PTS) WITH LYMPHOID MALIGNANCIES (2019) (0)
- Cancer Immunology at the Crossroads: Complementary Therapeutic Modalities Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? (2014) (0)
- 715P Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC) (2020) (0)
- Abstract SP012: Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine signaling inhibitors (2021) (0)
- A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). (2016) (0)
- IMMUNOTHERAPY IN CANCER 2 (2013) (0)
- 590 Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers (2022) (0)
- Abstract PR003: Single-cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy (2021) (0)
- Patterns of care and patient characteristics in postmenopausal women with HER2+ and hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2011) (0)
- Association of resistance to antiangiogenic therapy with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. (2015) (0)
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer (2018) (0)
- 744 Single cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy (2020) (0)
- Abstract 499: NanoString®GeoMx®digital spatial profiling further defines the role of B cells in the response to immune checkpoint blockade (2019) (0)
- A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC) (2019) (0)
- A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Abstract: AML‐024 (2017) (0)
- Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL) (2016) (0)
- Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis (2018) (0)
- Abstract 4488: Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors (2019) (0)
- The Tumor Microenvironment of Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients (2021) (0)
- 1305 Impact of Tet2-mutant clonal hematopoiesis on solid tumor immunology and response to checkpoint blockade (2022) (0)
- Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Padmanee Sharma?
Padmanee Sharma is affiliated with the following schools:
